alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 62, Number 62 (Tuesday, April 1, 1997)]
[Notices]
[Page 15475]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-8145]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY
[Docket No. RP97-4-005]


Panhandle Eastern Pipe Line Company; Notice of Compliance Filing

March 26, 1997.
    Take notice that on March 24, 1997, Panhandle Eastern Pipe Line 
Company (Panhandle) tendered for filing as part of its FERC Gas Tariff, 
First Revised Volume No. 1, the tariff sheets listed on Appendix A 
attached to the filing, proposed to be effective April 1, 1997. 
Panhandle asserts that the purpose of this filing is to comply with the 
Commission's order issued March 13, 1997 in Docket No. RP97-4-001, et 
al., 78 FERC para. 61,283 (1997).
    Panhandle states that copies of this filing are being served on all 
affected customers, applicable state regulatory agencies and all 
parties to this proceeding.
    Any person desiring to protest this filing should file a protest 
with the Federal Energy Regulatory Commission, 888 First Street, N.E., 
Washington, D.C. 20426, in accordance with Section 385.211 of the 
Commission's Rules and Regulations. All such protests must be filed in 
accordance with Section 154.210 of the Commission's Regulations. 
Protests will be considered by the Commission in determining the 
appropriate action to be taken, but will not serve to make protestants 
parties to the proceeding. Copies of this filing are on file with the 
Commission and are available for public inspection in the Public 
Reference Room.
Lois D. Cashell,
Secretary.
[FR Doc. 97-8145 Filed 3-31-97; 8:45 am]
BILLING CODE 6717-01-M
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

JUAN ANTONIO GONZALEZ

,

Appellant,

v.

THE STATE OF TEXAS

,

State

. §

§

§

§

§

§

§

'

' No. 08

- 1 4

- 00 293

- CR

Appeal from the

346 th District Court

of El Paso County, Texas

(TC# 20120D05048 )

O R D E R

The Court GRANTS the Appellant ’s motion for leave to file late brief until January 5

,

201 6

. NO FURTHER MOTIONS FOR LEAVE TO FILE LATE BRIEF WILL BE

CONSIDERED BY THIS COURT.

It is further ORDERED that the Hon. Ruben P. Morales , the Appellant ’s Attorney, pr epare

the Appellant ’s brief and forward the same to this Court on or before January 5 , 201 6

.

If the Appellant’s brief is not fi led with this Court by January 5 , 201 6 , this Court will find it

necessary to send this case back to the trial court for a hearin g as to why the Appellant’s brief has

not been filed.

IT IS SO ORDERED this 21 st day of December , 201 5

.

PER CURIAM

Before McClure, C.J., Rodriguez, and Hughes, JJ.
III 

111TH CONGRESS 

1ST SESSION S. RES. 258 

Commemorating the 100th anniversary of the University of Wisconsin-La 

Crosse. 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 10, 2009 

Mr. KOHL (for himself and Mr. FEINGOLD) submitted the following resolution; 

which was referred to the Committee on the Judiciary 

SEPTEMBER 14, 2009 

Committee discharged; considered and agreed to 

RESOLUTION 

Commemorating the 100th anniversary of the University of 

Wisconsin-La Crosse. 

Whereas La Crosse is located on the western border of middle-Wisconsin, on the east side of the Mississippi River; 

Whereas the first Europeans to see the site of La Crosse 

were French fur traders who traveled the Mississippi 

River in the late 17th century; 

Whereas La Crosse was incorporated as a city in 1856; 

Whereas Thomas Morris sponsored a bill in the Wisconsin 

State Senate that led to the creation of the current-day 

University of Wisconsin-La Crosse; 


srobinson on DSKHWCL6B1PROD with BILLS
2 

SRES 258 ATS 

Whereas the University of Wisconsin-La Crosse was founded 

in 1909 as the La Crosse State Normal School for the 

purpose of teacher preparation; 

Whereas the philosophy of Fassett A. Cotton, the university’s 

first president, was to train the whole person; 

Whereas ‘‘mens corpusque’’, Latin for ‘‘mind and body’’, is 

the motto on the university seal; 

Whereas the college changed its name to Wisconsin State 

College-La Crosse in 1951 when the Wisconsin State 

teachers colleges began awarding baccalaureate degrees 

in liberal arts; 

Whereas the University of Wisconsin-La Crosse offers 88 undergraduate programs in 44 disciplines and 26 graduate 

programs; 

Whereas the University of Wisconsin-La Crosse celebrated its 

50th anniversary in 1959, the same year that presidential 

candidate John F. Kennedy visited the campus and spoke 

to the student body in Graff Main Hall auditorium; 

Whereas U.S. News & World Report ranked the University 

of Wisconsin-La Crosse second among midwestern public 

universities offering bachelor’s and master’s degrees; 

Whereas the University of Wisconsin-La Crosse men’s athletic teams adopted the nickname ‘‘Eagles’’ in the fall of 

1989, and the women’s teams adopted that nickname a 

year later; 

Whereas the University of Wisconsin-La Crosse athletic 

teams have won 59 National Collegiate Athletic Association Division III titles in 9 different sports; and 


srobinson on DSKHWCL6B1PROD with BILLS
3 

SRES 258 ATS 

Whereas 2009 marks the 100th anniversary of the founding 

of the University of Wisconsin-La Crosse: Now, therefore, 

be it 

1 Resolved, That the Senate— 

2 (1) commemorates the 100th anniversary of the 

3 University of Wisconsin-La Crosse; and 

4 (2) commends the university for its status as a 

5 leading public university that excels in academics, 

6 athletics, and quality of life for students. 

Æ 


srobinson on DSKHWCL6B1PROD with BILLS
[Federal Register Volume 62, Number 62 (Tuesday, April 1, 1997)]
[Rules and Regulations]
[Page 15391]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-8116]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
21 CFR Parts 556 and 558


Animal Drugs, Feeds, and Related Products; Tilmicosin Phosphate 
Type A Medicated Article; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is correcting a final 
rule that appeared in the Federal Register of December 27, 1996 (61 FR 
68147). The document amended the animal drug regulations to reflect 
approval of Elanco Animal Health's new animal drug application (NADA) 
141-064 for use of a Type A medicated article containing tilmicosin 
phosphate in manufacturing a Type B or Type C medicated feed indicated 
for the control of swine respiratory disease associated with certain 
bacterial organisms. The document was published with some errors. This 
document corrects those errors.

EFFECTIVE DATE: December 27, 1996.

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for 
Veterinary Medicine (HFV-133), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-594-1644.

    In FR Doc. 96-32881, appearing on p. 68147, in the Federal Register 
of Friday, December 27, 1996, the following corrections are made:


Sec. 556.735  [Corrected]

    1. On page 68148, in the second column, in line 2, ``7.2'' is 
corrected to read ``7.5''.


Sec. 558.618  [Corrected]

    2. On page 68148, in the second column, in paragraph (d)(1), 
``181.8'' and ``363.6'' are corrected to read ``181'' and ``363'', 
respectively.

    Dated: February 7, 1997.
Robert C. Livingston,
Director, Office of New Animal Drug Evaluation, Center for Veterinary 
Medicine.
[FR Doc. 97-8116 Filed 3-31-97; 8:45 am]
BILLING CODE 4160-01-F
```

[Federal Register Volume 80, Number 121 (Wednesday, June 24, 2015)]
[Rules and Regulations]
[Page 36247]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-15481]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 63

National Emission Standards for Hazardous Air Pollutants for 
Source Categories

CFR Correction

    In Title 40 of the Code of Federal Regulations, Part 63 (Sec.  
63.8980 to end of part 63), revised as of July 1, 2014, on page 244, in 
Sec.  63.10686, paragraph (e) is reinstated to read as follows:

Sec.  63.10686  What are the requirements for electric arc furnaces and 
argon-oxygen decarburization vessels?

* * * * *
    (e) You must monitor the capture system and PM control device 
required by this subpart, maintain records, and submit reports 
according to the compliance assurance monitoring requirements in 40 CFR 
part 64. The exemption in 40 CFR 64.2(b)(1)(i) for emissions 
limitations or standards proposed after November 15, 1990 under section 
111 or 112 of the CAA does not apply. In lieu of the deadlines for 
submittal in 40 CFR 64.5, you must submit the monitoring information 
required by 40 CFR 64.4 to the applicable permitting authority for 
approval by no later than the compliance date for your affected source 
for this subpart and operate according to the approved plan by no later 
than 180 days after the date of approval by the permitting authority.

[FR Doc. 2015-15481 Filed 6-23-15; 8:45 am]
BILLING CODE 1505-01-D
```
Exhibit 3.1(m)
                                        
                                        
                           CERTIFICATE OF RETIREMENT
                              OF CERTAIN SHARES OF
                      SERIES B CUMULATIVE PREFERRED STOCK
                                      OF
                           RJR NABISCO HOLDINGS CORP.
                                        
                        (PURSUANT TO SECTION 243 OF THE
                       DELAWARE GENERAL CORPORATION LAW)
                                        


     In accordance with Section 243 of the General Corporation Law of the State
of Delaware, RJR Nabisco Holdings Corp., a Delaware corporation (the
"Corporation"), does hereby certify that the following resolutions respecting
its Series B Cumulative Preferred Stock were duly adopted by the Corporation's
Board of Directors:

     RESOLVED, that, following the exchange of 37,956.060 (Thirty-Seven Thousand
Nine Hundred Fifty-Six and Sixty One-Thousandths) shares of the Corporation's
Series B Cumulative Preferred Stock (the "Series B Cumulative Preferred Stock")
for the Corporation's 10% Junior Subordinated Debentures due 2044 on September 
21, 1995 (the "Exchange Date"), such shares of Series B Cumulative Preferred 
Stock will be retired and the reissuance of any such shares of Series B 
Cumulative Preferred Stock as part of such series of Preferred Stock will be 
prohibited under the Corporation's Amended and Restated Certificate of 
Incorporation; and

     RESOLVED, that, upon such retirement of 37,956.060 shares of Series B
Cumulative Preferred Stock effective on the Exchange Date, the officers of the
Corporation are hereby authorized, empowered and directed to file with the
Secretary of State of the State of Delaware a certificate pursuant to Section
243 of the General Corporation Law of the State of Delaware setting forth these
resolutions in order to reduce accordingly the number of authorized shares of
Series B Cumulative Preferred Stock.

IN WITNESS WHEREOF, RJR Nabisco Holdings Corp. has caused this Certificate to be
signed by Jo-Ann Ford, its Senior Vice President & Secretary, and attested by
Suzanne P. Jenney, its Assistant Secretary, this 11th day of October, 1995.



                                           By: /s/ Jo-Ann Ford
                                               -----------------------
                                               Jo-Ann Ford
                                               Senior Vice President & President


ATTEST:

/s/ Suzanne P. Jenney
-----------------------
Suzanne P. Jenney
Assistant Secretary
No. 11-11109.

#### Martin *v.*United States.

Ct. App. D. C. Certiorari denied.
III 

111TH CONGRESS 

1ST SESSION S. RES. 287 

Honoring the 25th anniversary of the enactment of the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman 

Act). 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 24, 2009 

Mr. BROWN submitted the following resolution; which was referred to the 

Committee on the Judiciary 

RESOLUTION 

Honoring the 25th anniversary of the enactment of the Drug 

Price Competition and Patent Term Restoration Act of 

1984 (the Hatch-Waxman Act). 

Whereas, on September 24, 1984, the Drug Price Competition and Patent Term Restoration Act of 1984 (Public 

Law 98–417; 98 Stat. 1585), commonly known as the 

Hatch-Waxman Act, was signed into law by President 

Ronald Reagan, at which time President Reagan indicated that generic drugs might save American consumers 

$1,000,000,000 over the next 10 years; 

Whereas this landmark law created the regulatory mechanism 

under which the Food and Drug Administration approves 

safe and affordable generic drugs; 


smartinez on DSKB9S0YB1PROD with BILLS
2 

•SRES 287 IS 

Whereas each year for the past quarter century, the generic 

pharmaceutical industry has delivered billions of dollars 

in savings on the purchase of prescription drugs, far exceeding the original estimate; 

Whereas a May 2009 report showed that during the preceding 10-year period, the use of generic drugs has saved 

the American health care system more than 

$734,000,000,000, with the most-recent annual average 

exceeding $121,000,000,000; 

Whereas generic drugs accounted for more than 72 percent 

of all prescription drugs dispensed, yet accounted for only 

17 percent of the spending on all prescription drugs, a 

differential that reflects the dramatically lower prices 

paid for generic drugs, which not only reduces consumer 

and taxpayer spending but also increases patient access 

to needed medicines; and 

Whereas while the Hatch-Waxman Act does not have an explicit pathway for approval by the Food and Drug Administration of lower-priced versions of cutting-edge biologic medicines, which account for a rapidly growing portion of prescription medicine spending, the Act does provide a solid framework for such a pathway: Now, therefore, be it 

1 Resolved, That it is the sense of Senate that— 

2 (1) enactment of the Hatch-Waxman Act (Pub3 lic Law 98–417; 98 Stat. 1585) in 1984 served to 

4 create the modern generic pharmaceutical industry, 

5 which has provided consumers with access to afford6 able drugs, yielding significant health and economic 

7 benefits for the Nation’s health care system; 


smartinez on DSKB9S0YB1PROD with BILLS
3 

•SRES 287 IS 

1 (2) Senator Orrin Hatch and Representative 

2 Henry Waxman deserve the Nation’s gratitude for 

3 authoring and championing this landmark bipartisan 

4 legislation; and 

5 (3) Congress should build on the work of these 

6 dedicated policymakers and enact legislation to cre7 ate a pathway for approval by the Food and Drug 

8 Administration of safe and affordable generic 

9 versions of biologic medicines. 

Æ 


smartinez on DSKB9S0YB1PROD with BILLS
Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350, as adopted), Jill M. Broadfoot, the Chief Financial Officer of Vical Incorporated (the Company), hereby certifies that, to the best of her knowledge:



| | 1. | The Companys Quarterly Report on Form 10-Q for the period ended September 30, 2009, to which this Certification is attached as Exhibit 32.2 (the
Periodic Report), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by
the Periodic Report and results of operations of the Company for the period covered by the Periodic Report.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dated:
November 6, 2009



|                       
|-----------------------
|/s/ JILL M. BROADFOOT  
|Jill M. Broadfoot      
|Chief Financial Officer

THIS CERTIFICATION ACCOMPANIES THE FORM 10-Q TO WHICH IT RELATES, IS NOT DEEMED FILED
WITH THE SEC AND IS NOT TO BE INCORPORATED BY REFERENCE INTO ANY FILING OF THE COMPANY UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (WHETHER MADE BEFORE OR AFTER THE DATE OF THE FORM 10-Q),
IRRESPECTIVE OF ANY GENERAL INCORPORATION LANGUAGE CONTAINED IN SUCH FILING. A SIGNED ORIGINAL OF THIS CERTIFICATION HAS BEEN PROVIDED TO THE COMPANY AND WILL BE RETAINED BY THE COMPANY AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR
ITS STAFF UPON REQUEST.
No. 12-5608.

#### Stewart *v.*Tucker, Secretary, Florida Department of Corrections.

C. A. 11th Cir. Certiorari denied.
# m94_40b
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<ARTICLE> 7
       
<S>                             <C>
<PERIOD-TYPE>                   09-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<DEBT-HELD-FOR-SALE>                            46,609
<DEBT-CARRYING-VALUE>                           14,455
<DEBT-MARKET-VALUE>                             15,234
<EQUITIES>                                       7,401
<MORTGAGE>                                          91
<REAL-ESTATE>                                        0
<TOTAL-INVEST>                                  72,538
<CASH>                                             302
<RECOVER-REINSURE>                               1,731
<DEFERRED-ACQUISITION>                           3,879
<TOTAL-ASSETS>                                 128,156
<POLICY-LOSSES>                                 55,483
<UNEARNED-PREMIUMS>                             22,183
<POLICY-OTHER>                                       0
<POLICY-HOLDER-FUNDS>                            1,933
<NOTES-PAYABLE>                                  5,592
<COMMON>                                            47
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          1
<OTHER-SE>                                      40,201
<TOTAL-LIABILITY-AND-EQUITY>                   128,156
<PREMIUMS>                                      32,208
<INVESTMENT-INCOME>                              3,251
<INVESTMENT-GAINS>                                 748
<OTHER-INCOME>                                     371
<BENEFITS>                                      31,305
<UNDERWRITING-AMORTIZATION>                      5,678
<UNDERWRITING-OTHER>                             5,195
<INCOME-PRETAX>                                (5,924) 
<INCOME-TAX>                                   (2,015) 
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,909)
<EPS-PRIMARY>                                    (.93)
<EPS-DILUTED>                                    (.93)
<RESERVE-OPEN>                                  48,964
<PROVISION-CURRENT>                             25,423 
<PROVISION-PRIOR>                                5,883
<PAYMENTS-CURRENT>                              10,836
<PAYMENTS-PRIOR>                                13,920
<RESERVE-CLOSE>                                 55,483
<CUMULATIVE-DEFICIENCY>                              0
        

</TABLE>
No. 11-9692.

#### Rana *v.*Department of the Army.

C. A. Fed. Cir. Motion for reconsideration of order denying leave to proceed *in forma pauperis*[566 U. S. 1020] denied. Leave to proceed as a veteran granted. Certiorari denied.
No. 11-10114.

#### Shannon *v.*Cate, Secretary, California Department of Corrections and Rehabilitation.

C. A. 9th Cir. Certiorari denied.
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 279 Agreed to Senate (ATS)]

111th CONGRESS
  1st Session
S. RES. 279

Making minority party appointments for certain committees for the 111th 
                               Congress.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 22, 2009

Mr. McConnell submitted the following resolution; which was considered 
                             and agreed to

_______________________________________________________________________

                               RESOLUTION

 
Making minority party appointments for certain committees for the 111th 
                               Congress.

    Resolved, That the following be the minority membership on the 
following committees for the remainder of the 111th Congress, or until 
their successors are appointed:
    Committee on Armed Services: Mr. McCain, Mr. Inhofe, Mr. Sessions, 
Mr. Chambliss, Mr. Graham, Mr. Thune, Mr. Wicker, Mr. LeMieux, Mr. 
Burr, Mr. Vitter, and Ms. Collins.
    Committee on Banking, Housing, and Urban Affairs: Mr. Shelby, Mr. 
Bennett, Mr. Bunning, Mr. Crapo, Mr. Corker, Mr. DeMint, Mr. Vitter, 
Mr. Johanns, Mrs. Hutchison, and Mr. Gregg.
    Committee on Commerce, Science, and Transportation: Mrs. Hutchison, 
Ms. Snowe, Mr. Ensign, Mr. DeMint, Mr. Thune, Mr. Wicker, Mr. LeMieux, 
Mr. Isakson, Mr. Vitter, Mr. Brownback, and Mr. Johanns.
    Special Committee on Aging: Mr. Corker, Mr. Shelby, Ms. Collins, 
Mr. Hatch, Mr. LeMieux, Mr. Brownback, Mr. Graham, and Mr. Chambliss.
                                 <all>
```
No. 12-5770.

#### Shields v. United States.

C. A. 6th Cir. Certiorari denied.